<DOC>
	<DOCNO>NCT02132897</DOCNO>
	<brief_summary>Controlled release Carbamazepine ( CBZ ) antiepileptic , antineuralgic mood stabilizer drug . The CR formulation CBZ slowly absorb elimination half life varies time due metabolism autoinduction . The primary objective study estimate bioequivalence new brand generic product ( Auration ( R ) CR ) 400 mg manufacture Uruguay vs. innovative product ( Tegretol ( R ) CR ) 400 mg manufacture Brasil , feed condition . The secondary objective evaluation safety issue . The study design randomize two sequence , two period crossover . For power le 80 % sample size estimate 20 healthy male subject . Products administer food ( high calories/high fat breakfast ) overnight fast . Time vs. concentration curve build subject formulation Area Under Curve ( AUC0240 ) estimate use trapezoid rule , AUC 0-inf . ( time 0 infinity ) estimate use formula Cz/Ke , Cmax take individual curve . This parameter statistically process WinNonlin 6.3 Pharmacokinetics/Statistic software order prove bioequivalence study product .</brief_summary>
	<brief_title>Fed Bioequivalence Study CBZ Formulations</brief_title>
	<detailed_description />
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>Nonsmoking smoker less 5 cigarettes/day , within age range 18 50 year . Body Mass Index ( BMI = weight/height2 ) great equal 18.5 kg/m2 less equal 24.9 kg/m2 . No clinically significant finding physical examination , 12lead electrocardiogram ( ECG ) vital sign ( blood pressure 100140/5890 mmHg , heart rate 5099 beats/min , temperature 35.8ºC 37.6ºC , respiration rate 12 20 breaths/minute ) No clinical laboratory value outside acceptable range per protocol , unless Principal Investigator Subinvestigator decide clinically significant ( NCS ) . Availability subject entire study period willingness subject adhere protocol requirement . The subject agree abstain alcohol , coffee food drink contain methylxanthines ( mate , tea , cola , chocolate ) 48hours , grapefruit contain food beverage 72 hour prior study drug administration study period . Known history hypersensitivity Carbamazepine and/or relate drug . Positive test hepatitis B surface antigen , hepatitis C HIV . Known history gastrointestinal ( e.g : gastritis , inflammatory bowel disease , celiac disease ) , cardiac , pulmonary , endocrine , musculoskeletal , neurological , hematological , immunological , hepatic renal disease , malignancy , unless deem NCS Principal Investigator Subinvestigator . Any history peptic ulcer disease gastrointestinal ( GI ) bleeding . Any history gastrointestinal surgery ( except appendectomy ) . Presence significant physical organ abnormality . Any illness 4 week study , unless deem NCS Clinical Investigator Subinvestigator . Any history evidence psychiatric psychological disease , unless deem NCS Clinical Investigator Subinvestigator . Any history asthma ( 12 year age ) . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug . Any history drug psychoactive medicine abuse . Any recent history alcohol abuse ( less 1 year ) . Use prescription medication within 14 day precede study . Use vaccination within 30 day precede study . Use overthecounter ( OTC ) medication within 7 day precede study ( except spermicidal/barrier contraceptive product , sunscreen sunblock product ) . Participation plasma donor plasmapheresis program within 7 day precede study . Blood donation within 60 day precede study . Participation clinical trial investigational drug within 180 day precede study , agreement participate clinical trial 180 day study . Intolerance venipuncture .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Antiepileptic</keyword>
	<keyword>Carbamazepine</keyword>
	<keyword>Bio-equivalence</keyword>
	<keyword>Fed</keyword>
	<keyword>Crossover</keyword>
</DOC>